Hims & Hers Health, Inc.

Hims & Hers acquires consumers online, connects them with licensed providers, and fulfills prescribed or wellness products through pharmacies and partners, earning mostly self-pay revenue from recurring treatments across U.S. and international brands.

Ticker

HIMS

Company

Hims & Hers Health, Inc.

Exchange

NYSE

Listing

listed

Sector

Consumer Health / Telehealth & Pharmacy

The bull case is that Hims & Hers can use its consumer funnel, subscriber base, fulfillment network and expanding care categories to generate repeat revenue and operating leverage. The countercase is that U.S. contraction, margin pressure, GLP-1 enforcement, acquisition obligations and potential dilution make that growth less predictable.S1S2S3S4S6S7S10S11S12

• Hims & Hers Health, Inc. is listed on the New York Stock Exchange under HIMS. Its largely self-pay platform markets care online, connects customers with licensed providers, and fulfills prescribed and wellness products through affiliated or partner pharmacies across categories that include sexual health, hair, weight loss, dermatology and mental health.S1S2
• The affiliated U.S. medical groups are separately physician-owned and retain clinical control. Hims & Hers provides nonclinical administrative services and consolidates the groups as variable interest entities for accounting purposes; consolidation does not mean Hims & Hers controls clinical decisions.S1
• Fiscal 2025 revenue was $2.348 billion, up 59% from $1.477 billion. U.S. revenue was $2.214 billion, up 53%, and rest-of-world revenue was $134.0 million, up 399%.S1
• Fiscal 2025 gross profit was $1.733 billion and gross margin was 74%, down from 79% in 2024. Operating income was $105.6 million and net income was $128.4 million.S1
• Fiscal 2024 included a $54.3 million income-tax benefit. The comparison was affected by a $68.0 million decrease in the valuation allowance, primarily from the release against domestic deferred-tax assets and partly offset by other tax activity, so year-over-year GAAP net income is not a clean measure of operating progress.S1
• Management reported fiscal 2025 adjusted EBITDA of $318.0 million. Operating cash flow was $300.0 million, but management-defined free cash flow was only $57.4 million after $226.0 million of property, equipment and intangible-asset purchases and $16.5 million invested in website development and internal-use software.S1
• Hims & Hers ended 2025 with 2.511 million subscribers, up 13%, and monthly revenue per average subscriber of $83, up 28%.S1
• Fiscal 2025 marketing expense was $919.3 million. The company separately labels $798.5 million of advertising and media spend as customer acquisition costs, equal to 34.01% of revenue; that figure is total spend, not disclosed acquisition cost per new customer.S1
• Q1 2026 revenue was $608.1 million, up 4% year over year. U.S. revenue fell 8% to $529.9 million, while rest-of-world revenue rose 969% to $78.2 million.S2S3
• Q1 GAAP gross margin fell to 65% from 73%. Cost of revenue included $28.5 million of restructuring charges; management's adjusted gross margin, which excludes those charges, was 70%.S2S3
• Q1 operating loss was $78.3 million, net loss was $92.1 million and diluted loss per share was $0.40. Management reported adjusted EBITDA of $44.3 million, or 7% of revenue, versus $91.1 million and 16% a year earlier.S2S3
• The Q1 adjusted-EBITDA reconciliation included $36.9 million of stock-based compensation, $33.5 million of restructuring costs, $22.0 million of depreciation and amortization and a $15.0 million legal accrual, among other adjustments.S2S3
• Q1 operating cash flow was $89.4 million and management-defined free cash flow was $53.0 million. At March 31, cash and cash equivalents of $222.3 million plus $528.6 million of short-term available-for-sale investments totaled $750.9 million.S2S3
• Q1 subscribers reached 2.584 million, up 9%, while monthly revenue per average subscriber fell 6% to $80. The numerator includes one-time-customer revenue while one-time customers are excluded from the subscriber count; management said excluding that revenue would reduce the metric by approximately $10.S2S3
• Management guided Q2 2026 revenue to $680 million to $700 million and adjusted EBITDA to $35 million to $55 million. Full-year guidance was $2.8 billion to $3.0 billion of revenue and $275 million to $350 million of adjusted EBITDA. The guidance explicitly excluded Eucalyptus and is a forecast, not achieved performance.S3
• On March 9, 2026, Hims & Hers said it would stop advertising compounded GLP-1 treatments and focus its U.S. weight-loss offering on FDA-approved branded products, while reserving limited patient-specific compounding for cases management says are clinically necessary. Novo Nordisk separately confirmed a branded Wegovy collaboration.S4S5
• FDA's September 9, 2025 warning letter said Hims & Hers compounded-semaglutide claims about the same active ingredient and clinically proven ingredients were false or misleading and caused the products to be misbranded. FDA also states that compounded drugs are not FDA approved.S6
• FDA said on April 1, 2026 that Section 503A generally bars regular or inordinate production of drugs that are essentially copies unless a prescriber documents a significant difference for an identified patient. FDA's stated enforcement policy uses four or fewer prescriptions per compounded product per calendar month as the threshold at which it does not intend to act on that specific restriction. Semaglutide and tirzepatide were not then on the 503B bulks list or shortage list.S7
• FDA named Hims & Hers in a February 6, 2026 enforcement statement and warned that unresolved violations could lead to seizure or injunction. On April 30, FDA proposed, but had not yet finalized, excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list.S8S9
• Company filings disclose active FTC settlement discussions and a $15.0 million accrual; Hims & Hers says the final liability could materially exceed that amount and cannot be reasonably estimated. The filings also disclose an HHS referral to the Department of Justice and an SEC enforcement investigation concerning compounded semaglutide and related business relationships. These are unresolved matters, not findings of liability.S1S2
• Hims & Hers announced completion of the Eucalyptus acquisition on June 2, 2026. The agreement set consideration of up to approximately $1.15 billion, subject to net-debt, working-capital and other contractual adjustments: about $240 million upfront, $710 million in six deferred installments over 18 months and up to $200 million of earnout payments, with some deferred or earnout amounts eligible for stock settlement. Separate from purchase consideration, the agreement provides for up to $100 million of post-close employee restricted-stock-unit awards.S10S11
• Hims & Hers described Eucalyptus as having an annual revenue run-rate above $450 million. The exhibit defines that non-GAAP measure as unaudited annualized January 2026 gross fulfilled billings, including customer products and services processed on Eucalyptus platforms; it is not audited annual GAAP revenue or revenue already earned by Hims & Hers.S15
• The company had $1.0 billion principal amount of 0% convertible notes due 2030 at March 31. It issued another $402.5 million of 0% convertible notes due 2032 in May, with an initial conversion price of approximately $29.53 per share and issuer-elected cash, share or mixed settlement. Convertible principal is debt, not immediate issued-share dilution.S1S2S12
• The 2026 proxy says founder Andrew Dudum held 87.73% of combined voting power. Class A shares carry one vote each and Class V shares carry 175 votes each, making Hims & Hers a controlled company under NYSE rules.S13
• On July 1, two subsidiaries entered a receivables-purchase agreement with JPMorgan carrying a $400 million facility limit and an initial 364-day term. JPMorgan may decline purchases in its sole discretion, so the headline limit is neither cash already received nor committed revenue.S14
• On July 17, Hims & Hers announced that chief accounting officer Irene Becklund would depart effective October 9, 2026 and then serve as an advisor during the transition. The company said CFO Yemi Okupe would assume the chief accounting officer responsibilities in the interim while it searches for a permanent successor. The announcement did not report a restatement, control deficiency or accounting disagreement.S16

• narrativeBull-case interpretation: Hims & Hers could become a broad consumer-health distribution layer, using its subscriber base, fulfillment network and multiple care categories to cross-sell more products at lower incremental acquisition cost. That is an investment thesis, not a reported outcome.
• narrativeBear-case interpretation: the U.S. shift from mass-marketed compounded GLP-1s toward branded products and shorter fulfillment cadences may structurally lower gross margin even if it reduces one regulatory risk. The long-run margin effect is not quantified company guidance.
• narrativeEucalyptus may restore faster consolidated growth and expand Hims & Hers internationally, but its economics are not yet proven in Hims & Hers filed consolidated results. Eucalyptus's issuer-described annual revenue run-rate is unaudited annualized gross fulfilled billings, not GAAP revenue already earned by Hims & Hers.
• narrativeFounder voting control, convertibles and acquisition-related stock settlement may limit minority-shareholder influence and increase per-share dilution if execution disappoints. This is a capital-structure interpretation, not a forecast that every potential security will be issued or converted.

• ▸GLP-1 compounding and enforcement risk is current. FDA has issued a warning letter, named Hims & Hers in an enforcement statement, narrowed post-shortage compounding conditions and proposed excluding major GLP-1 substances from the 503B bulks list. The April 30 action remains a proposal, not a final determination.S4S6S7S8S9
• ▸Product mix and fulfillment cadence can pressure margins. Gross margin fell from 79% in 2024 to 74% in 2025 and 65% GAAP in Q1 2026; management linked Q1 pressure partly to weight-loss mix, shorter cadences, product costs and shipping, but has not established a normalized future margin.S1S2S3
• ▸Government investigations and consumer-protection matters could produce fines, injunctions, operating restrictions, disclosure risk and legal expense. Hims & Hers says the FTC outcome may materially exceed its $15.0 million accrual and cannot estimate the excess range.S1S2S6S8
• ▸Advertising intensity remains high. Marketing expense was $919.3 million and company-defined customer-acquisition spend was $798.5 million in 2025. Rising media costs, weaker conversion or tighter advertising rules could slow growth or reduce contribution margin.S1
• ▸Most sales are subscription based, but customers can cancel or snooze. One-time revenue is included in the monthly-revenue-per-subscriber numerator while one-time buyers are excluded from subscribers, and cadence changes affect revenue timing. Hims & Hers does not disclose a category-level churn series.S1S2S3
• ▸The U.S. medical groups are separately physician-owned and retain clinical control while Hims & Hers consolidates them as VIEs. State corporate-practice-of-medicine and fee-splitting rules, prescribing requirements, pharmacy inspections, quality failures or recalls could disrupt the platform.S1
• ▸Eucalyptus adds multi-country integration risk plus approximately $710 million of deferred payments and a possible $200 million earnout. Stock settlement can protect cash but dilute shareholders; cash settlement can tighten liquidity. Separate from purchase consideration, the agreement also provides for up to $100 million of post-close employee restricted-stock-unit awards, creating another dilution and compensation-cost channel.S10S11
• ▸Convertible and equity instruments can dilute shareholders. Potential securities disclosed at Q1 included restricted stock units, options, warrants and 2030-note conversion shares; the later 2032 notes add another conversion layer. Capped calls mitigate, rather than eliminate, dilution within stated price caps, and the instruments should not be blindly summed without resolving overlap, vesting and settlement assumptions.S2S12
• ▸The platform handles sensitive health information across several jurisdictions and uses data- and AI-assisted workflows. Hims & Hers says its consumer platform generally is not itself a HIPAA covered entity or business associate under its operating model, but it remains subject to contractual, state, FTC and international privacy obligations.S1
• ▸March 31 liquidity was about $750.9 million, but receivables rose sharply while accounts payable and deferred revenue supported operating cash flow. The later $400 million receivables facility is discretionary for JPMorgan and should not be presented as cash already available.S2S14
• ▸Founder voting control limits ordinary shareholders' influence over governance, board composition and strategic decisions even though economic ownership is lower than voting power.S13
• ▸The announced chief accounting officer transition creates financial-reporting continuity and succession risk. The release provides transition arrangements but does not itself report a restatement, control deficiency or accounting disagreement, so no such cause should be inferred from the departure alone.S16

Telehealth

— healthcare delivered through remote digital consultations and related services; the term describes the channel, not a guarantee that a particular treatment is appropriate or approved

Subscriber / Monthly Revenue per Average Subscriber

— Hims & Hers counts a subscriber with at least one active recurring-billing subscription; its monthly-revenue metric divides total revenue, including one-time-customer revenue, by average subscribers and months in the period, so it is not pure subscription-only ARPU

Gross Margin / Adjusted Gross Margin

— gross margin is gross profit divided by revenue; adjusted gross margin is management's non-GAAP version after excluding specified costs, so the excluded items and the GAAP comparison matter

Adjusted EBITDA

— a company-defined non-GAAP earnings measure that removes interest, taxes, depreciation, amortization and several additional items; it should be read beside GAAP income and cash flow, especially when exclusions are large

Free Cash Flow

— Hims & Hers defines this non-GAAP measure as operating cash flow minus purchases of property, equipment and intangible assets and investment in website development and internal-use software; it is not the same as net income

Customer Acquisition Costs

— Hims & Hers uses this label for total advertising and media spending; it is not disclosed as dollars per newly acquired customer and should not be treated as cohort CAC without more data

GLP-1 Receptor Agonist

— a class of medicines that mimics the GLP-1 hormone and is used in approved products for diabetes or obesity depending on the drug and label; product approval does not make every use, formulation or compounded version FDA approved

Compounded Drug

— a medication prepared for a patient by a pharmacy or outsourcing facility under statutory conditions; compounded drugs are not FDA approved and FDA does not review them before marketing in the same way as approved drugs

503A Pharmacy

— a state-licensed pharmacy or physician compounder operating under Section 503A, generally for an identified individual patient based on a prescription and subject to restrictions on making essentially copies of commercially available drugs

503B Outsourcing Facility

— an FDA-registered outsourcing facility that may compound under Section 503B but faces current good-manufacturing-practice and reporting requirements plus limits on the bulk substances it can use; registration does not make each compounded drug FDA approved

Variable Interest Entity (VIE)

— an entity consolidated for accounting because the reporting company directs the activities that most affect its economics and absorbs relevant gains or losses, even without owning voting control; accounting consolidation does not transfer clinical control

Convertible Senior Note

— debt that may convert into shares under specified conditions; Hims & Hers can settle its 2032-note conversions in cash, shares or a combination, so eventual dilution depends on share price, conversion terms and settlement choice

Capped Call

— an option transaction bought by the issuer to offset some conversion-related dilution or cash cost; protection stops at the cap price and does not erase the note principal or every possible dilution outcome

Annual Revenue Run-Rate (ARR)

— an annualized snapshot of current-period activity, not audited annual GAAP revenue; Eucalyptus's stated run-rate annualized unaudited January 2026 gross fulfilled billings and should not be inserted into Hims & Hers revenue as though already earned

Deferred Consideration / Earnout

— deferred consideration is acquisition price paid after closing; an earnout is additional consideration payable only if contractual milestones are met, and either can consume future cash or be settled partly in shares if the agreement allows it

Dual-Class Share Structure

— a capital structure in which share classes carry different voting rights; Hims & Hers Class A carries one vote per share and Class V carries 175, allowing founder voting control to exceed economic ownership